Testosterone Therapy in Men An update

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Testosterone Therapy in Men An update"

Transcription

1 Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO

2 Presenter Disclosure None

3 Objectives identify appropriate candidates for testosterone replacement therapy monitor testosterone replacement therapy acknowledge side-effects of testosterone therapy

4 FDA Drug Safety Communication requiring labeling change to inform of possible increased risk of heart attack and stroke with use, March 3, 2015 Testosterone is an F.D.A.-approved replacement therapy only for men with disorders of the testicles, pituitary gland or brain that cause hypogonadism Testosterone should not be used to relieve symptoms in men who have low testosterone for no reasons other than aging. Health care professionals should make patients aware of the possible increased cardiovascular risk when deciding whether to start or continue a patient on testosterone therapy.

5 Decline in Testosterone with age

6 SHBG (nmol/l) Albuminbound T 50% Free T 3% BMI (kg/m2) SHBG-bound T 47% SHBG (nmol/l) Total testosterone should be measured by liquid chromatography tandem mass spectrometry Free Testosterone should be separated by equilibrium dialysis Calculated Free Testosterone (using total testosterone, SHBG and albumin) is also reliable (normal range ng/dl) AGE (years)

7 European Male Aging Study Secondary hypogonadism is more common than primary hypogonadism at all ages. Hypogonadism was defined based on low T and not symptoms Tajar et al; J Clin Endocrinol Metab, April 2010, 95(4):

8 The Syndrome of Late-Onset Hypogonadism as defined by at least three sexual symptoms and total T of <320 ng/dl and free T of <6.3 ng/dl Wu et al; N Engl J Med 2010;363:

9 Normal range of Total and Free Testosterone concentrations Young (19-40 years) healthy non-obese men (n=456) (Framingham Study Cohort) Total Testosterone (ng/dl) Free Testosterone (ng/dl) Elderly (70-89 years) healthy men (n=394) Health in Man Study (Australia) Total Testosterone (ng/dl) Free Testosterone (ng/dl) 2.5 th percentile th percentile Mean (SD) 724 (221) 14.2 (4.5) 412 (141) 5.7 (1.5) Median Total testosterone was measured using LC-MS/MS. Free testosterone was calculated using SHBG and albumin. Bhasin et al; J Clin Endocrinol Metab, August 2011, 96(8): Yeap et al, J Clin Endocrinol Metab, November 2012, 97(11): Healthy older men were those reporting excellent or very good health and who also had no history of smoking, diabetes, CVD, cancer, depression, or dementia.

10 Probability of dying from any cause according to plasma levels of Testosterone in elderly men (3690 community-dwelling men aged 70 to 89 years) * * * Quartile Quartile Quartile 3 Quartile 4 0 Total T calculated Free T Quartiles Total T (ng/dl) Calculated Free T (ng/dl) optimal range of total T: ng/dl Yeap, J Clin Endocrinol Metab, January 2014, 99(1):E9 E18

11

12 The Testosterone Trials The T trials are a coordinated set of seven double blind randomized placebo controlled trials conducted at twelve US sites. 790 men older than 65 years of age who were symptomatic and had subnormal total testosterone concentration were randomized to receive testosterone (Androgel 1%) or placebo gel for a year. To enroll, subjects had to qualify on the basis of symptoms in one of the three main trials (sexual function trial, physical function trial, or the vitality trial). Other four trials: cognitive function, anemia, bone density and cardiovascular risk factors The dose of testosterone gel was adjusted to keep the concentration within the normal range for young men (19 to 40 years of age).

13

14

15

16

17 Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction and low testosterone These data do not support the routine addition of testosterone to a PDE5 inhibitor therapy to improve erectile response in men with ED and low testosterone levels. Ann Intern Med Nov 20;157(10):

18 Older Men Are as Responsive as Young Men to the Anabolic Effects of Graded Doses of Testosterone on the Skeletal Muscle Changes from baseline in FFM, fat mass, leg press strength, and skeletal muscle mass in young (black bars) and older (grey bars) men in response to graded doses of testosterone enanthate. Healthy, young (n=54) and older men (n=52) were randomized to receive a long-acting GnRH agonist plus one of five different doses of testosterone enanthate (25, 50, 125, 300, and 600 mg weekly, im) for 20 wk. J Clin Endocrinol Metab, February 2005, 90(2):

19

20

21 The Testosterone in Older Men with Mobility Limitations (TOM) trial Minimal clinically Important Difference Changes in gait speed without a load and stair-climbing power without a load did not differ significantly between the groups. Basaria et al, NEJM, 2010

22

23

24 Testosterone Treatment did not affect Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment JAMA, 2017;317(7):

25 Testosterone vs Placebo Treatment for 12 Months and Hemoglobin Concentrations in Participants in the Anemia Trial Testosterone treatment resulted in erythrocytosis (Hg >17.5 g/dl) only in nonanemic men, in 6 (2%) of 336 participants. Four of those 6 had serum T >800 ng/dl when erythrocytosis was detected. Roy et al, JAMA Internal Med, 2017

26 Snyder et al, JAMA Intern Med., 2017

27 Treatment with 1mg anastrazole or placebo in elderly hypogonadal men for one year (JCEM 2009)

28 Treatment with 1mg anastrazole or placebo in elderly hypogonadal men for one year: effect on bone mineral density (JCEM 2009)

29 PSA and Testosterone Does Testosterone replacement increase PSA? ~30%; increases PSA to normal levels. An average increase in serum PSA levels of about 0.30 ng/ml in young hypogonadal men 0.43 ng/ml in older hypogonadal men PSA (µg/l) upper normal limit Does Testosterone increase prostate volume? ~15% untreated hypogonadal men testosterone-treated hypogonadal men PSA in untreated hypogonadal men (n=47), testosterone-treated hypogonadal men (n=78), and age-matched normal men (n=75) Behre et al. Clin Endocrinol 1994 Testosterone replacement therapy has not been shown to cause an increase in incidence of BPH or prostate cancer in underpowered trials of relatively short duration (<3 years). 0 normal men

30 Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism JAMA Randomized, double-blind, placebo-controlled trial of 44 men, aged 44 to 78 years Serum testosterone levels lower than 300 ng/dl Participants received 150 mg of testosterone or matching placebo intramuscularly every 2 weeks for 6 months

31 Saturation model The saturation model suggests that testosterone is like water for a thirsty tumor. Once thirst is quenched, additional water serves only as excess. The saturation point occurs at approximately 8 nmol/l (approximately 250 ng/dl)

32

33 Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta- Analysis; Fernandez-Balsells et al, JCEM 2010 Continuous outcomes Weighted mean difference Lower boundary Prostate symptom scale PSA change (ng/ml) HDL cholesterol (mg/dl) LDL cholesterol (mg/dl) Fasting triglycerides (mg/dl) Total cholesterol (mg/dl) Fasting glucose Systolic blood pressure Diastolic blood pressure Upper boundary

34 The annual rate of major adverse cardiovascular event (MI, stroke death due to cardiovascular causes) was 1.7% in both groups (7 men out of 394 in each group), a rate which would be expected in an elderly population, 20% of whom had history of myocardial infarction or stroke prior to entering the study. During a follow-up period of one year of observation after discontinuation of treatment, 2 men in testosterone group and 9 men in placebo had a cardiovascular event. While these data are reassuring, T trials are not long enough to provide definite evidence of cardiovascular safety after testosterone therapy in elderly men. Snyder et al, NEJM 2016

35 Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low T, JAMA. 2017;317(7):

36

37 Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial; Basaria et al, JAMA men 60 years or older low or low-normal total testosterone levels ( ng/dl) OR free testosterone <50 pg/ml) 156 participants were randomized to receive 7.5 g of 1% testosterone and 152 were randomized to receive placebo gel packets daily for 3 years. The dose was adjusted to achieve testosterone levels between 500 and 900 ng/dl. Coprimary outcomes included common carotid artery intimamedia thickness and coronary artery calcium; secondary outcomes included sexual function and health related quality of life.

38

39 Overview of the metaanalyses A: cardiovascular events B: stroke C: mortality Lancet Diabetes and Endocrinology, November 2016

40 Effect of appropriate testosterone replacement therapy on MI, stroke and mortality in men with low testosterone P=0.005 P=0.03 P<0.001 Mean duration of treatment:- normalized-trt 3.0±2.7 years non-normalized T 1.5±1.9 years P<0.001 untreated MI Stroke mortality normalized T non-normalized T Number of subjects: Untreated (13,378), normalized T (43,931), non-normalized T (25,701) Sharma R et al. Eur Heart J, 2015

41 [June 2014] The U.S. Food and Drug Administration (FDA) is requiring manufacturers to include a general warning in the drug labeling of all approved testosterone products about the risk of blood clots in the veins (DVT and PE). The risk of venous blood clots is already included in the labeling of testosterone products as a possible consequence of polycythemia. Because there have been postmarket reports of venous blood clots unrelated to polycythemia, FDA is requiring a change to drug labeling of all testosterone products to provide a more general warning regarding venous blood clots. Testosterone Replacement Therapy and the Incidence of DVT and Pulmonary Embolism: A Retrospective Cohort Study from VA Normal on-treatment stt Group (Gp1): Adequately treated patients: 38,362. Low on-treatment stt Group (Gp2): Inadequately treated patients: 22,191. Untreated Subjects (Gp3): subjects with low baseline stt but who did not receive any TRT during the study period: 10,854 The incidence of DVT/PE was 0.5%, 0.4%, and 0.4% in Gp1, Gp2, and Gp3, respectively.

42 FDA (March 2015): We are requiring manufacturers of approved testosterone products to conduct a well-designed clinical trial to more clearly address the question of whether an increased risk of heart attack or stroke exists among users of these products. We are encouraging these manufacturers to work together on a clinical trial, but they are allowed to work separately if they so choose. On the basis of the cardiovascular event rates reported in the largest systematic meta-analysis, any randomized controlled trial aiming to detect a true difference in cardiovascular risk between treatment groups receiving exogenous testosterone and their controls would require at least 17,664 participants in each trial group. (Onasanya et al, Lancet D&E, Nov 2016) Will one randomized controlled trial resolve this issue?

43 SUMMARY FDA recommends that only organic hypogonadism be treated. TRT should be titrated to achieve serum total testosterone concentrations of ~700 in young (<40 years) men and ~400 ng/dl in elderly (>70 years) men. TRT can cause polycythemia There is no definitive evidence that TRT increases or decreases cardiovascular events.

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone

More information

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research

More information

Point-Counterpoint: Late Onset Hypogonadism (LOH)

Point-Counterpoint: Late Onset Hypogonadism (LOH) Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx

More information

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008

More information

ANDROGEN DEFICIENCY Update on Evaluation and Management

ANDROGEN DEFICIENCY Update on Evaluation and Management ANDROGEN DEFICIENCY Update on Evaluation and Management Kristen Gill Hairston, MD, MPH Associate Professor of Internal Medicine Section of Endocrinology and Metabolism Wake Forest University School of

More information

10 Essential Blood Tests PART 2

10 Essential Blood Tests PART 2 Presents 10 Essential Blood Tests PART 2 The Blood Chemistry Webinars With DR. DICKEN WEATHERBY Creator of the Blood Chemistry Software Heart Disease, Inflammation, & Essential Blood Tests #2 to #4: Fibrinogen,

More information

Recognizing and Managing Testosterone Deficiency

Recognizing and Managing Testosterone Deficiency Recognizing and Managing Testosterone Deficiency J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships

More information

Take-Home Messages: Androgens

Take-Home Messages: Androgens Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical

More information

EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE

EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics

More information

Clinical Trial Synopsis TL-OPI-518, NCT#

Clinical Trial Synopsis TL-OPI-518, NCT# Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride

More information

Estrogens vs Testosterone for cardiovascular health and longevity

Estrogens vs Testosterone for cardiovascular health and longevity Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in

More information

HORMONE THERAPY IN AGING MALE ATHLETES

HORMONE THERAPY IN AGING MALE ATHLETES DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.

Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd. 4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant

More information

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Depression and Sexuality in Aging Men

Depression and Sexuality in Aging Men Depression and Sexuality in Aging Men Prof. Dr. Michael Zitzmann Andrologist, Endocrinologist, Diabetologist Sexual Medicine (FECSM) Clinical Andrology / Centre for Reproductive Medicine and Andrology,

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health

More information

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital

Androgen deficiency. Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Androgen deficiency Dr Rakesh Iyer Staff Specialist in Endocrinology Calvary hospital Outline Pathological androgen deficiency - Background, causes, interpretation - Indications for treatment Androgen

More information

6/14/2010. GnRH=Gonadotropin-Releasing Hormone.

6/14/2010. GnRH=Gonadotropin-Releasing Hormone. Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Alternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY

Alternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY eajannini@gmail.com What hypogonadism is? What hypogonadism is? It is an empty glass The two

More information

Tables of Normal Values (As of February 2005)

Tables of Normal Values (As of February 2005) Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital

Late onset Hypogonadism. Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

Vascular Diseases. Overview: Selected Slides

Vascular Diseases. Overview: Selected Slides Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

Multiphasic Blood Analysis

Multiphasic Blood Analysis Understanding Your Multiphasic Blood Analysis Test Results Mon General thanks you for participating in the multiphasic blood analysis. This test can be an early warning of health problems, including coronary

More information

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,

More information

Placebo-Controlled Statin Trials

Placebo-Controlled Statin Trials PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of

More information

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP

Vitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals

More information

Metastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942

Metastatic disease. 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Prostate cancer Metastatic disease 80% will die of prostate cancer 5 year survival only 25% No major advances in cure since 1942 Impact of early prostate cancer 12 10 8 6 4 2 0 70-80 years 60-70 years

More information

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system LEARN Learn about HTHU Level 3 and the point system 01 IDENTIFY Identify the major risk factors for cardiovascular disease and how to improve our cardiovascular health 03 02 ACT Begin our Session 1 Goal

More information

GUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde

GUIDELINES ON. Introduction. G.R. Dohle, S. Arver, C. Bettocchi, S. Kliesch, M. Punab, W. de Ronde GUIDELINES ON Male Hypogonadism G.R. Dohle, S. Arver,. Bettocchi, S. Kliesch, M. Punab, W. de Ronde Introduction Male hypogonadism is a clinical syndrome caused by androgen deficiency. It may adversely

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

Prevention of Heart Disease: The New Guidelines

Prevention of Heart Disease: The New Guidelines Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015

More information

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??

More information

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine

More information

Cardiovascular Diseases and Diabetes

Cardiovascular Diseases and Diabetes Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular

More information

Chemistry Reference Ranges and Critical Values

Chemistry Reference Ranges and Critical Values Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl

More information

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD. Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of

More information

INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY

INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY The use of hormone therapy for gender transition/affirmation is based on many years of experience treating trans persons. Research on hormone therapy is

More information

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary 2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth

More information

Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549

Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549 2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes

More information

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults

More information

Drug Class Review Newer Oral Anticoagulant Drugs

Drug Class Review Newer Oral Anticoagulant Drugs Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal

Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal JoAnn E. Manson, MD, DrPH, FAHA Chief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine i and dthe Michael

More information

The Endocrine Society Guidelines

The Endocrine Society Guidelines Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS

More information

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening

More information

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University

More information

Management of Chronic Idiopathic Urticaria

Management of Chronic Idiopathic Urticaria 9/3/216 Management of Chronic Idiopathic Urticaria Brian Berman, M.D., Ph.D. Professor Emeritus of Dermatology and Dermatologic Surgery, University of Miami Co-Director Center for Clinical and Cosmetic

More information

Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products.

Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. Male Menopause: Disease or Pseudoscience? March 4, 2015 story: FDA to require warning on labels of testosterone products. 3-30-2015; web William E. Winter, MD University of Florida Departments of Pathology

More information

NEW GUIDELINES FOR CHOLESTEROL

NEW GUIDELINES FOR CHOLESTEROL NEW GUIDELINES FOR CHOLESTEROL NEW CHOLESTEROL GUIDELINES 2013 Recently updated guidelines for the treatment of high blood cholesterol levels is a major update since 2002. The news media have trumpeted

More information

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health

More information

REVERSE HEART DISEASE - HEART ATTACK CURE & STROKE CURE - LOWER HIGH BLOOD PRESSURE TO NORMAL & RESTORE YOUTHFUL CARDIAC HEALTH WITH NO SURGERY OR

REVERSE HEART DISEASE - HEART ATTACK CURE & STROKE CURE - LOWER HIGH BLOOD PRESSURE TO NORMAL & RESTORE YOUTHFUL CARDIAC HEALTH WITH NO SURGERY OR REVERSE HEART DISEASE - HEART ATTACK CURE & STROKE CURE - LOWER HIGH BLOOD PRESSURE TO NORMAL & RESTORE YOUTHFUL CARDIAC HEALTH WITH NO SURGERY OR DRUGS... Pressure Cure, The End Of Heart Disease) By Christopher

More information

BSO, HRT, and ERT. No relevant financial disclosures

BSO, HRT, and ERT. No relevant financial disclosures BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures

More information

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo

Androderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine

Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant

More information

HIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School

HIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School HIV Infection as a Chronic Disease Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School Role of Primary Care Approximately 50,000 patients are diagnosed with HIV infection annually

More information

Cholesterol Management Roy Gandolfi, MD

Cholesterol Management Roy Gandolfi, MD Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians

More information

Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS

Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS Before using medications to transition and feminize, you need to know the possible advantages, disadvantages and risks

More information

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date:

Clinical Policy: Testosterone Pellet (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: Clinical Policy: (Testopel) Reference Number: CP.CPA.## [Pre-P&T approval] Effective Date: 07.25.17 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

Diabetes and Heart Disease

Diabetes and Heart Disease Diabetes and Heart Disease Sarah Alexander, MD Assistant Professor of Medicine Division of Cardiology Rush University Medical Center 2/8/2017 Rush is a not-for-profit health care, education and research

More information

AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)

AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does

More information

Rick Fox M.A Health and Wellness Specialist

Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Metabolism is the process your body uses to get or make energy from the food you eat. Food is made up of proteins, carbohydrates

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:

More information

Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D.

Update on Androgen Deficiency. Acknowledgments. Curatio PowerPoint TemplateControversies in Male Hypogonadism Bradley D. The General Practice Education Day Healthed / Generation Next August 22 nd Sydney Update on Androgen Deficiency Robert I. McLachlan, FRACP, PhD Director, Andrology Australia Principal Research Fellow,

More information

Low T? Late Onset Hypogonadism

Low T? Late Onset Hypogonadism University of Vermont ScholarWorks @ UVM Family Medicine Clerkship Student Projects College of Medicine 2014 Low T? Late Onset Hypogonadism Cheng-Wei Huang University of Vermont Follow this and additional

More information

C-Reactive Protein and Your Heart

C-Reactive Protein and Your Heart C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory

More information

Cardiovascular Disease: an Overview. Jon W. Wahrenberger, MD February 2, 2008

Cardiovascular Disease: an Overview. Jon W. Wahrenberger, MD February 2, 2008 Cardiovascular Disease: an Overview Jon W. Wahrenberger, MD February 2, 2008 The Good News We are living longer! Heart & stroke death rates are falling! Changing demographics So Why Worry about Cardiovascular

More information

Implementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines

Implementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines Summary Implementing new Dyslipidemia Guidelines Implementation of CV Risk and Dyslipidemia Guidelines Ronald D. Scott, MD Regional KPSC CVD Co-Lead Family Medicine and Lipidology, WLA ASCVD (Atherosclerotic

More information

Frequency of Dyslipidemia and IHD in IGT Patients

Frequency of Dyslipidemia and IHD in IGT Patients Frequency of Dyslipidemia and IHD in IGT Patients *Islam MS, 1 Hossain MZ, 2 Talukder SK, 3 Elahi MM, 4 Mondal RN 5 Impaired glucose tolerance (IGT) is often associated with macrovascular complications.

More information

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital

More information

7.L.1.4 Circulatory System Guided Study Notes. Circulation

7.L.1.4 Circulatory System Guided Study Notes. Circulation 1 7.L.1.4 Circulatory System Guided Study Notes Circulation Sect. 1: The Body s Transport System Sect. 2: A Closer Look at Blood Vessels Sect. 3: Blood and Lymph Sect. 4: Cardiovascular Health Sect. 1:

More information

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

GH Replacement Therapy in Growth Hormone Deficient Adults

GH Replacement Therapy in Growth Hormone Deficient Adults GH Replacement Therapy in Growth Hormone Deficient Adults Sequence of hormone loss in hypopituitarism depending on location of a benign tumor Besser GM, Cudworth AG, eds. Clinical endocrinology: an illustrated

More information

CONTRIBUTING FACTORS FOR STROKE:

CONTRIBUTING FACTORS FOR STROKE: CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING

More information

SESSION 5 2:20 3:35 PM

SESSION 5 2:20 3:35 PM SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related

More information

Management of Cardiovascular Disease in Diabetes

Management of Cardiovascular Disease in Diabetes Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western

More information

Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS)

Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS) Clinical Interventions in Aging open access to scientific and medical research Open Access Full Text Article Original Research Testosterone replacement therapy among elderly males: the Testim Registry

More information

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE

More information

Unit 5 Cardiovascular System Exam Version 2

Unit 5 Cardiovascular System Exam Version 2 2014-2015 Unit 5 Cardiovascular System Exam Version 2 5.1 Identify the components and physical characteristics of the blood. 1. Most of the volume of normal human blood is: a. hormones b. plasma c. leukocytes

More information

C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School

C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School Novel Strategies to Prevent Pulmonary Embolism and DVT: APEX Trial and Substudies C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School Conflict of Interest Statement 2 Present Research/Grant

More information

What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?

What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,

More information

Low HDL and Diabetic Dyslipidemia

Low HDL and Diabetic Dyslipidemia The Lowdown: Low HDL and Diabetic Dyslipidemia Patients with diabetes commonly have a low-density lipoprotein cholesterol (LDL-C) no higher than that of the general population. What treatment is warranted

More information

Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men:

Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men: Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men: The Kuopio Ischaemic Heart Disease Risk Factor Study Jaakko Mursu, Jyrki K. Virtanen, Tiina H. Rissanen,

More information